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Bagsværd, DenmarkA B S T R A C TObjectives: To analyze the health economic implications of increas-
ing the proportion of patients with type 2 diabetes meeting treatment
targets for glycemia, blood pressure, and serum lipid levels in Mexico.
Methods: Complication rates, life expectancy, quality-adjusted life
expectancy, and costs were projected over patient lifetimes using a
published and validated diabetes model (with outcomes discounted at
5% annually). Baseline cohort characteristics were derived from the
Mexican cohort of A1chieve. Scenarios in which 20% to 80% of the
patients achieved glycemic targets (glycosylated hemoglobin [HbA1c]
level of 7%) only, or blood pressure and lipid targets (based on
international guidelines) in addition to glycemic targets were com-
pared with current standard of care. Results: Increasing the propor-
tion of patients meeting Hb A1c targets was projected to increase
mean life expectancy and quality-adjusted life expectancy by up to
0.60 years and 0.34 quality-adjusted life-years over current care. When
patients achieved all treatment targets, clinical beneﬁts were greateree front matter Copyright & 2015, International S
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ndence to: Barnaby Hunt, Ossian Health Economicthan when only the Hb A1c level was controlled. Increasing the
proportion of patients reaching the glycemic target was projected to
lead to cost savings over conventional treatment, reducing mean
costs by up to Mexican pesos 42,389 (US $3314). Surprisingly, bringing
patients to other targets, as well as the Hb A1c target, did not result in
greater cost savings. This was as a result of the increased life expect-
ancy in these simulations, leading to greater costs in the ﬁnal years
(survival paradox). Conclusions: Increasing the proportion of patients
achieving treatment targets resulted in improved clinical outcomes
and cost savings from a health care payer perspective in
Mexico.
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The 2012 Encuesta Nacional de Salud y Nutrición (ENSANUT), a
national health survey carried out every 6 years since 1986, found
that approximately 6.4 million adults had a diagnosis of diabetes
mellitus in Mexico, representing 9.2% of the adult population [1].
Moreover, the prevalence of diabetes in Mexico is increasing
rapidly, with the number of people identiﬁed with the disease
doubling since 2000 [1]. The clinical impact of diabetes in Mexico
is large, with the International Diabetes Federation estimating
that the disease is associated with more than 70,000 deaths per
annum [2]. In addition to a substantial and growing clinical
burden, diabetes is associated with a signiﬁcant economic
impact. It has been estimated that in 2013 health care expendi-
ture as a result of diabetes in Mexico was more than US $7 billionand this is predicted to grow to almost US $11 billion by 2035 [2].
The key driver of health care expenditure as a result of diabetes is
the cost of treating diabetes-related complications [2].
Historically, Mexico has had a mixed health care system, with
a mixture of public and private hospitals providing care for the
population [3].This was, however, associated with inequality,
with access to care, quality of care, and out-of-pocket expendi-
ture depending on income and geographical location. Since the
introduction of health reforms in 2003, Mexico has been working
toward a system of universal health care coverage, and in 2012
(following the enrollment of 52.6 million previously uninsured
citizens) provision for universal coverage was provided in the
budget [4]. Health care is now funded by three institutions: the
Mexican Institute for Social Security, the Institute for Social
Security and Services for Civil Servants, and the Seguro Popular.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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has been suggested that these could be merged in the future to
create a single health care payer in Mexico.
The key challenges in the successful treatment of type 2
diabetes (and therefore reducing the risk of diabetes-related
complications) include maintaining tight glycemic control and
controlling cardiovascular risk factors such as blood pressure,
serum lipid levels, and body mass index. Beneﬁts of this multi-
factorial approach to disease management have been shown in a
number of studies, such as the Steno-2 study that found that
intensive multifactorial treatment reduced the risk of cardiovas-
cular and microvascular complications [5–7]. To reﬂect the
importance of multifactorial risk reduction, a number of
evidence-based guidelines and position statements have been
released by the International Diabetes Federation, the American
Diabetes Association, and the European Association for the Study
of Diabetes [8–10]. These recommendations move away from the
traditional glucocentric approach to the management of diabetes
and provide blood pressure and blood lipid targets in addition to
glycemic targets. Landmark studies such as Action to Control
Cardiovascular Risk in Diabetes (ACCORD) and Action in Diabetes
and Vascular Disease: Preterax and Diamicron MR Controlled
Evaluation (ADVANCE) have evidenced the importance of blood
pressure control in lowering the risk of cardiovascular and renal
events [11,12]. Treatment options for controlling blood pressure
include lifestyle therapy, angiotensin-converting enzyme inhib-
itors, and angiotensin receptor blockers. Patients with type 2
diabetes have an increased prevalence of dyslipidemia, with
evidence showing the beneﬁt of achieving normal levels. The
ﬁrst priority in dyslipidemia therapy is to reduce low-density
lipoprotein (LDL) cholesterol, with a meta-analysis of 14 random-
ized trials ﬁnding that for each 1 mmol/L reduction in LDL
cholesterol, the risk of vascular mortality fell by 13% over a 4-
year period [13]. The evidence in favor of management of high-
density lipoprotein (HDL) cholesterol and triglycerides is less
robust, although patients with hypertriglyceridemia should
receive corrective therapy. Statins form the ﬁrst-line treatment
for controlling dyslipidemia, with ﬁbrates and niacin available as
additional therapies if required.
Data from the ENSANUT survey and A1chieve (a 60,000-patient,
global, prospective, observational study of basal, meal-time, and
biphasic insulin analogues in daily clinical practice in patients
with type 2 diabetes) suggest that getting patients with type 2
diabetes to treatment target in Mexico is challenging [1,14]. The
aim of the present analysis was to evaluate the long-term clinical
and cost implications of increasing the proportion of patients with
type 2 diabetes reaching glycemic targets alone, and increasing the
proportion of patients reaching glycemic, blood pressure, and
blood lipid targets in Mexico. Scenarios in which care was
improved were compared with current standard of care, deﬁned
as physiological risk factor measurements and frequency of severe
and nonsevere hypoglycemic events remaining at the values on
enrollment in the A1chieve study, before following progression
algorithms to determine long-term changes.Methods
Model Description
The analysis was performed using the CORE Diabetes Model (IMS
Health, Basel, Switzerland), the architecture, assumptions, fea-
tures, and capabilities of which have been previously published
[15]. It is a validated, nonproduct-speciﬁc diabetes policy analysis
tool and is based on a series of interdependent submodels that
simulate the complications of diabetes (angina, myocardial
infarction, congestive heart failure, stroke, peripheral vasculardisease, diabetic retinopathy, macular edema, cataract, hypogly-
cemia, ketoacidosis, lactic acidosis, nephropathy and end-stage
renal disease, neuropathy, foot ulcer and amputation, and non-
speciﬁc mortality). Each submodel has a semi-Markov structure
and uses time, state, time-in-state, and diabetes type-dependent
probabilities derived from published sources. Monte Carlo simu-
lation using tracker variables overcomes the memoryless proper-
ties of the standard Markov model, and allows interconnectivity
and interaction between individual complication submodels. The
model takes into account mortality as a result of diabetes-related
complications and background mortality, through user-
modiﬁable life tables (based on 2011 WHO life tables for Mexico
in the present analysis). Projected outcomes include complication
rates, life expectancy, quality-adjusted life expectancy, and costs.
Long-term outcomes projected by the model have been validated
against real-life data in 2004 and more recently in 2012 [16,17].
Simulation Cohort
The baseline cohort was based on the Mexican cohort of the
A1chieve study. The study provides a wealth of data across a
range of countries to assess diabetes treatment. Furthermore, the
study has minimal inclusion and exclusion criteria (only patients
currently receiving one of the insulin analogues evaluated in the
study or women who were or intended to become pregnant were
excluded), and therefore aimed to enroll a representative pop-
ulation. Data from the 531 patients enrolled in Mexico identiﬁed
that only 5% of the enrolled patients were achieving a glycosy-
lated hemoglobin (Hb A1c) target of 7% (as recommended in
treatment guidelines) [14].
To represent current standard of care in Mexico, physiological
risk factor measurements and frequency of severe (where
patients require assistance from a third party) and nonsevere
hypoglycemic events at enrollment in the trial were used, that is,
before patients were allocated insulin as per the trial protocol,
with no changes applied (the baseline cohort characteristics used
in the analysis are provided in Supplemental Materials found at
http://dx.doi.org/10.1016/j.vhri.2015.01.001. The cohort contained
a mixture of insulin-naive patients receiving oral antidiabetes
medications and patients receiving insulin (basal, basal-bolus, or
premixed). The use of tobacco and alcohol within the cohort was
based on World Health Organization reports [18,19].
Treatment Effects
No single treatment guideline provided guidance on all input
variables to the CORE Diabetes Model, and therefore synthesized
treatment targets of the Hb A1c level of less than 7%, systolic
blood pressure of less than 130 mmHg, total cholesterol level of
less than 4 mmol/L, HDL-cholesterol level of more than 1 mmol/L,
LDL-cholesterol level of less than 2 mmol/L, and triglyceride level
of less than 1.7 mmol/L were used [8–10]. Based on these treat-
ment guidelines, scenarios in which 20%, 40%, 60%, and 80% of
the patients achieved a glycemic target of 7% (with all other
parameters remaining at baseline) were compared with remain-
ing at baseline. In addition, scenarios in which the same propor-
tion of patients achieved blood pressure and blood lipid targets in
addition to glycemic targets were evaluated.
The CORE Diabetes Model contains an inbuilt functionality to
alter the proportion of patients achieving an Hb A1c target. The
model uses a gamma distribution, truncated at the lower end with
a tail toward the higher Hb A1c value. The model, however, does
not have equivalent functionality for other variables, for which a
mean change from baseline must be speciﬁed. It was assumed that
systolic blood pressure, HDL-cholesterol, and LDL-cholesterol
would best be represented by gamma distributions, and total
cholesterol and triglycerides would best be represented by normal
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plot the distributions, which were then shifted until the appropri-
ate proportion of patients reached treatment targets. The change
from baseline was then calculated for each modeled variable in
each scenario. Following application of the initial treatment effect,
it was assumed that parameters followed the natural progression
algorithms of the CORE Diabetes Model, which are based on the
United Kingdom Prospective Diabetes Study (UKPDS) and the
Framingham Heart Study, with the exception of Hb A1c, which
was assumed to remain constant. This approach was chosen
because it represents a patient achieving and maintaining glycemic
control over the long term, as a result of improved care. Data from
a number of long-term studies suggest that this can be achieved,
particularly in patients receiving insulin [20–22]. A number of
studies have demonstrated that reduced Hb A1c level is often
accompanied by an increased frequency of hypoglycemia. Based
on a recent meta-analysis, it was assumed that the frequency of
nonsevere hypoglycemic events increased by 1.4 events per patient
per year for every 1% reduction in Hb A1c level [23]. In the current
standard of care arm, parameters remained at the baseline value in
the ﬁrst year, before following the CORE Diabetes Model progres-
sion equations as in other analyses. All treatment effects applied in
the analyses can be found in Supplemental Materials found at
http://dx.doi.org/10.1016/j.vhri.2015.01.001.
Costs and Utilities
Costs of treating diabetes-related complications were accounted
from a third-party health care payer perspective in 2011 Mexican
pesos (MXN). Values are also presented in US dollar, based on an
exchange rate of US $1 ¼ MXN 12.79 (reﬂecting the exchange rate
in the cost year of the analysis). As a theoretical analysis, the
costs of diabetes medications to bring patients to treatment
target were not included. Costs of diabetes-related complications
were taken from a cost collection study carried out in Mexico
based on recently published diagnosis related groups (all costs
used in the analysis are presented in Supplemental Materials
found at http://dx.doi.org/10.1016/j.vhri.2015.01.001) [24]. There-
fore, only costs to the health care system are included, with no
costs to individuals captured. Utilities and disutilities (i.e., meas-
ures of the impact on quality of life) associated with complica-
tions of diabetes were obtained from the literature and, where
possible, from populations with type 2 diabetes mellitus (full
details of the utilities used can be found in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2015.01.001)
[15,25–27].
Statistical Approach, Time Horizon, And Other Model Settings
A simulated cohort of 1000 patients was run through the model
1000 times for each simulation, with mean values and SDs
generated for long-term outcomes. The time horizon was set to
patient lifetimes in the base case (the model takes into account
mortality from diabetes-related complications and background
mortality) to capture all relevant long-term complications, and
associated costs, to assess their impact on life expectancy and
quality-adjusted life expectancy. This is in line with recommen-
dations on the modeling of diabetes [28]. Future costs and clinical
beneﬁts were discounted symmetrically by 5% per annum in line
with published health economic guidance for Mexico [29].Results
Bringing Patients To The Hb A1c Target Only
Increasing the proportion of patients reaching glycemic targets
was found to improve life expectancy and quality-adjusted lifeexpectancy in all scenarios investigated (Figs. 1 and 2). Bringing
20% of the patients to an Hb A1c target of 7% was associated with
an increase in discounted life expectancy to 7.65 years versus 7.62
years with current standard of care. In the same scenario, mean
quality-adjusted life expectancy was increased by 0.01 quality-
adjusted life-years (QALYs) (95% conﬁdence interval [CI] 0.005–
0.015 QALYs) over 5.69 QALYs with current standard of care.
Bringing 80% of the patients to the glycemic target was associated
with a mean discounted life expectancy increase of 0.34 years
(95% CI 0.328–0.348 years) and a mean quality-adjusted life
expectancy increase of 0.16 QALYs (95% CI 0.155–0.168 QALYs).
Clinical beneﬁts over current care resulted chieﬂy from the
avoidance of diabetes-related complications as a result of
improved glycemic control. Of particular note was the reduction
in the incidence of end-stage diabetes-related complications. The
relative risk of developing end-stage complications when 80% of
the patients achieved the glycemic target compared with current
standard of care was 0.56 for severe vision loss, 0.36 for end-stage
renal disease, 0.86 for amputation, 0.94 for stroke, and 0.79 for
myocardial infarction. In addition to the reduced incidence of
diabetes-related complications, improved treatment was associ-
ated with delayed onset of complications (Fig. 3). By both
reducing the incidence and delaying the onset of diabetes-
related complications, increasing the proportion of patients
meeting treatment targets results in increased life expectancy
and quality-adjusted life expectancy.
Increasing the proportion of patients achieving glycemic
targets was projected to result in cost savings over current
standard of care (Fig. 5). Current standard of care was associated
with mean direct medical costs of MXN 815,876 (US $63,795;
95% CI MXN 814,347–817,406). The largest element of the cost
burden was hypoglycemia, comprising 32% of the total, at
MXN 257,063 (US $20,100). Diabetic foot complications and oph-
thalmic complications represented other key drivers of health
care costs, at MXN 209,035 (US $16,345) and MXN 166,789 (US
$ 13,041), respectively. Cost savings became greater as a greater
proportion of patients achieved the glycemic target, increasing
from MXN 2231 (US $ 174; 95% CI MXN 501–3961) per patient
when 20% of the patients achieved an Hb A1c target of 7% and
becoming as large as MXN 42,389 (US $3314; 95% CI MXN 40,231–
44,547) per patient when 80% of the patients achieved glycemic
targets. The key driver of cost savings was reduced costs as a
result of renal complications avoided, representing between 74%
and 82% of the total cost saving. The second largest driver of cost
savings was as a result of ophthalmic complications avoided,
comprising between 17% and 35% of the total cost saving. The
cost of hypoglycemic events was increased in the scenarios in
which an increased proportion of the patients reached Hb A1c
targets, growing from MXN 257,063 (US $20,100) when patients
received current standard of care to as much as MXN 269,881 (US
$21,102).
Bringing Patients To All Targets
In the scenarios in which patients achieved blood pressure and
blood lipid targets in addition to glycemic targets, life expectancy
and quality-adjusted life expectancy were increased compared
with not only current standard of care but also scenarios in which
only Hb A1c targets were met (Figs. 1 and 2). In the scenario in
which 80% of the patients achieved all targets, mean discounted
life expectancy was found to increase by 0.61 years (95% CI 0.60–
0.62 years) compared with current standard of care, whereas
mean quality-adjusted life expectancy was found to increase by
0.35 QALYs (95% CI 0.35–0.36 QALYs). As in the scenarios in which
patients achieved only the glycemic target, the avoidance of
diabetes-related complications was key in improving clinical
outcomes. The relative risk for severe vision loss, end-stage renal
Fig. 1
Fig. 2
Fig. 3
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0.33, 0.89, 0.49, and 0.13, respectively, when 80% of the patients
reached all targets compared with current standard of care.
These relative risks are lower than in the scenario in which
patients achieved only the glycemic target, reﬂecting the impor-
tance of multifactorial control. Bringing patients to all targets was
also associated with increased time to onset of complications,
both compared with current standard of care and when only
glycemic targets were achieved (Fig. 4).
Bringing patients to all targets was also associated with cost
savings compared with current standard of care (Fig. 6). As in
scenarios in which patients achieved only Hb A1c targets, avoided
costs of renal complications resulted in the greatest cost savings.
The cost savings as a result of avoided cardiovascular complica-
tions, however, were more signiﬁcant than when only Hb A1c
targets were achieved, with savings as high as MXN 12,113 (US
$947). Surprisingly, overall cost savings were not as high as when
only glycemic targets were achieved. A key driver of this was the
increased cost of hypoglycemia, as patients lived longer and
therefore experienced an increased number of hypoglycemic
events. The cost of treating diabetic foot complications was
higher than in the current care arm, and the cost savings as a
result of other complications avoided were lower than when only
glycemic targets were met. This was as a result of the survival
paradox, in which increased life expectancy results in increased
costs in the later years of life.Discussion
The results of the present theoretical analysis suggest that
increasing the proportion of patients reaching glycemic targets
improved clinical outcomes over current standard of care in
Mexico, with life expectancy and quality-adjusted life expectancy
increased. Bringing patients to blood pressure and blood lipid
targets as well as glycemic targets resulted in greater improve-
ments in clinical outcomes compared with when only glycemia
was controlled. Improving treatment resulted in reduced inci-
dence and delayed onset of complications. Of particular note was
the identiﬁed reduction in the cumulative incidence of myocar-
dial infarction, falling from 14.5% when patients received current
standard of care to less than 2% when 80% of the patients
reached all treatment targets. Improving the proportion of
patients meeting treatment targets resulted in cost savings over
patient lifetimes compared with current care. Interestingly,
bringing patients to all treatment targets resulted in smaller cost
savings than when only glycemic targets were met. This was due
to the survival paradox, in which increased life expectancy
results in increased costs in the later years of life. This was
particularly driven by the cost of treating hypoglycemia.
Although the most dramatic improvements in life expectancy
and quality-adjusted life expectancy are observed when 80% of
the patients achieve treatment targets (either glycemic control or
all targets), these are ambitious and may not be readily achieved
in clinical practice. The results of the analyses with 20% and 40%
of the patients achieving targets may be more applicable to the
Mexican setting. In these analyses, important gains in quality-
adjusted life expectancy and reductions in direct costs were
observed. It should be noted that even relatively small improve-
ments in physiological parameters can result in improved clinical
outcomes and cost savings.
There are a number of limitations to the present theoretical
analysis that must be considered. As an exploratory analysis, we
have assumed that the distribution of patients for each variable
in our analysis remains the same as the proportion of patients
achieving target increases. This implies that all patients, irre-
spective of their baseline measurement, improve by the sameamount to bring the appropriate proportion of patients to target.
This may, however, underestimate the improvements seen in
patients in poorest control at baseline, who have the potential to
show far greater improvements than those patients already in
good control. Therefore, the present analysis may be conserva-
tive, with this limitation applying to both the scenarios in which
only glycemic control was improved and in which all targets were
met. As a theoretical analysis, sensitivity analysis was not
considered appropriate because the analysis is based on assumed
changes, rather than values obtained in a clinical trial, which
may be uncertain.
A key aspect of the present analysis is how well the A1chieve
baseline population matches the poorly controlled population
with type 2 diabetes in Mexico. The A1chieve data set forms a key
source for health economic modeling because it provides a
detailed, country-speciﬁc set of inputs from 531 patients in
Mexico. Although the ENSANUT data provide an overview of
patients with type 2 diabetes in Mexico, it does not contain the
detailed data required to carry out a health economic analysis.
Data from the national survey suggest that in 2012 approximately
25% of the patients with diabetes achieved an Hb A1c target of 7%,
a signiﬁcant increase from the 3% of adults achieving the target
in 2006. Within the A1chieve cohort, 5% of the patients were
found to be achieving the glycemic target at baseline. It may be
the case that patients in the A1chieve study were in worse
control than the general population with type 2 diabetes in
Mexico. This is to be expected because the A1chieve study aimed
to recruit patients who were considered to have uncontrolled
diabetes. As a result, the present analysis may overestimate the
clinical improvements that can be made in the general popula-
tion with type 2 diabetes in Mexico. The analysis, however, is
highly relevant to patients with type 2 diabetes who are currently
poorly controlled. This is the subgroup of the population with
diabetes that has the most to gain, in terms of quality-adjusted
life expectancy, from even small improvements in treatment.
They are also the population with the highest cost of treating
diabetes-related complications. The present analysis identiﬁes
that signiﬁcant cost savings from a health care payer perspective
can be made as a result of improving treatment for these
patients.
As glycemic control improves, patients with diabetes often
experience an increase in hypoglycemic episodes. To capture this
in the present analysis it was assumed that for every 1%
reduction in the Hb A1c level a patient experienced 1.4 further
hypoglycemic events per year [23]. This was based on a meta-
analysis of three randomized controlled trials comparing alter-
native insulin regimens. Increased hypoglycemia on improved
glycemic control is dependent on the medication received. For
example, the glucagon-like peptide-1 receptor agonists and the
dipeptidyl peptidase-4 inhibitors are associated with a low risk of
hypoglycemia, whereas sulfonylureas and insulin are associated
with a higher risk of hypoglycemia [10]. The increase in hypo-
glycemia that may be seen if glycemic control were to be
improved in Mexico would depend on the interventions used to
achieve this. The ENSANUT study found that most of the patients
in Mexico are treated with oral medications, with a very low
proportion of patients receiving insulin (around 15%) [1]. Increas-
ing the proportion of patients receiving insulin may represent a
key method for improving glycemic control in patients with type
2 diabetes in Mexico, and therefore the meta-analysis used may
represent an appropriate source for parameterizing the model.
The analysis does not capture glycemic variability because the
CORE Diabetes Model does not contain this functionality. This
remains, however, a controversial area. Glycemic variability has
been linked to mortality in critically ill patients without diabetes,
but a recent review concluded that there was no supporting
evidence for targeting glycemic variability separately from the Hb
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suggested that treatments to reduce glycemic variability may
reduce the incidence of hypoglycemia and therefore the fre-
quency of self-monitoring of blood glucose may be reduced,
resulting in a cost saving and lessening the burden on patients.
A ﬁnal limitation of the analysis is that the cost of increasing
the proportion of patients achieving treatment targets (i.e.,
intervention costs) was not included. This was not possible
because the analysis was theoretical rather than based on a
speciﬁc treatment. Bringing patients to treatment targets requires
increased resource use, such as medications, increased physician
time, and increased laboratory testing. In ACCORD, it was found
that in the intensive group a mean of 3.4 medications per patient
were received compared with 2.1 medications per patient in the
conventional arm [11]. A key question for health care payers is
whether the increased short-term medical costs of achieving
treatment targets will be sufﬁciently offset by the avoided cost of
diabetes-related complications in the long term, so that the
interventions would be considered cost-effective. The analysis
provides useful data on the potential cost savings that may offset
the increased cost of improving diabetes treatment in Mexico, but
it cannot be considered a full economic evaluation because not
all relevant costs of achieving the treatment targets are captured.
On this basis, the treatments that improve risk factor control may
be useful in the treatment of patients with type 2 diabetes in
Mexico from both a patient and a health care payer perspective.
The present analysis has quantiﬁed the per-patient savings that
can be made as a result of improved treatment, and this
represents available budget that could be used to improve
diabetes care in Mexico without a net increase in health care
expenditure. With direct cost savings of up to MXN 42,000 per
patient over patient lifetimes, there is potentially a signiﬁcant
fund available to improve the therapy that patients with type 2
diabetes receive in Mexico. Despite the limitations of the analy-
sis, the present approach represents the best available method of
assessing the long-term implications of improved care for
patients with diabetes in Mexico, and the conclusions are likely
to be valid. Improving treatment by bringing patients to
glycemic, blood pressure, and blood lipid targets is likely to
result in improved clinical outcomes and substantial cost sav-
ings. The acquisition cost of therapies that bring patients to one
or more treatment targets should not be a barrier to their use
because the increased pharmacy cost is likely to be offset by cost
savings as a result of avoided complications in the later
years of life.
If improved care for patients with type 2 diabetes in Mexico is
to be realized, treatment patterns may have to change. As part of
the ENSANUT survey, data are collected on a number of quality-
of-care indicators. In 2012, it was estimated that only 7.7% of the
population with type 2 diabetes received an Hb A1c measurement
two or more times per year [1]. It may be the case that a
signiﬁcant proportion of patients with type 2 diabetes are not
aware that they have poor glycemic control, and that increasing
the frequency and proportion of patients receiving the HbA1c
measurement could result in improved glycemic control because
patients and clinicians have the information required to enable
them to titrate treatment appropriately. The other targets con-
sidered in the analysis show a similar pattern, with less than half
(44%) of the population with type 2 diabetes receiving a blood
pressure measurement at least once a month and 30% of the
population not receiving annual cholesterol and triglyceride
measurements [1]. Although pharmacological treatment is
important in the treatment of type 2 diabetes, guidelines advo-
cate the use of lifestyle management as a ﬁrst line of treatment
and alongside long-term drug regimens. This is an area in which
care can be improved in Mexico, with only 7% of the patients
having a formal diet and exercise plan, less than 4% of thepatients with elevated blood pressure receiving advice on reduc-
ing salt intake, and only 6% of the patients with dyslipidemia
receiving advice on reducing cholesterol [1]. To increase the
proportion of patients with type 2 diabetes achieving treatment
targets and therefore realize the potential clinical and economic
beneﬁts, care patterns in Mexico may have to change. The
ENSANUT survey collects data on quality of care and can be used
to promote and monitor improved care.
The present analysis suggests that improved treatment is
associated with an increased cost of treating hypoglycemia (due
to the survival paradox, with patients experiencing increased
events due to increased life expectancy). Therefore, avoidance of
hypoglycemia should form a key treatment target in Mexico.
Costs predominantly arose from severe hypoglycemia, which has
a high cost of treatment in Mexico [24]. If the incidence of severe
hypoglycemia can be reduced as glycemic control is improved,
then cost savings will be larger than identiﬁed in the present
analysis. For example, if the cost of treating severe hypoglycemia
was kept constant, cost savings of almost MXN 50,000 per patient
could be made in the scenario in which 80% of the patients
achieved all treatment targets. Hypoglycemic events and the
subsequent fear of hypoglycemic events may represent a barrier
to improved glycemic control, but if this barrier can be overcome,
through the use of diabetes medications associated with a low
risk of hypoglycemia, the potential beneﬁt for both patients and
health care payers is large.
The present long-term modeling analysis has suggested that
improving the proportion of patients with type 2 diabetes
achieving glycemic, blood pressure, and blood lipid targets in
Mexico has the potential to result in substantial increases in
duration and quality of life, primarily as a result of reduced
incidence and delayed onset of diabetes-related complications.
Moreover, these clinical improvements result in cost savings
from a health care payer perspective. Optimizing the treatment
of patients with type 2 diabetes in Mexico must form a key
clinical objective in the coming years. The ENSANUT survey will
provide a valuable method for tracking progress made in this
regard.
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